Content
November 2024, Volume 8, Issue 6
- 787-792 Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of Life
by Ellen Kim DeLuca & Ann Chen Wu & Kurt D. Christensen & Davene R. Wright & Jennifer Yeh & Hadley Stevens Smith - 793-808 A Systematic Review of the Impact of Spinal Cord Injury on Costs and Health-Related Quality of Life
by Modou Diop & David Epstein - 809-822 Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore
by Clarence Ong & Jamaica Briones & Zhi Zhen Lim & Nisha Suyien Chandran & Haur Yueh Lee & Benny Kaihui Li & Yik Weng Yew & Hwee-Lin Wee - 823-836 Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses
by Fatemeh Mirzayeh Fashami & Jean-Eric Tarride & Behnam Sadeghirad & Kimia Hariri & Amirreza Peyrovinasab & Mitchell Levine - 837-845 Economic Impact of Bladder Cancer in the USA
by Otavio Clark & Tulio Sarmento & Anthony Eccleston & Julia Brinkmann & Renato Picoli & Vamsi Daliparthi & Jorine Voss & Sanjana Chandrasekar & Allison Thompson & Jane Chang - 847-856 Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
by Matilde Slot & Thomas Bøjer Rasmussen & Mette Nørgaard & Carsten Schade Larsen & Lars Holger Ehlers - 857-867 Clinicians’ Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment
by Alexander Keenan & Chiara Whichello & Hoa H. Le & David M. Kern & Gabriela S. Fernandez & Vicky Turner & Anup Das & Matt Quaife & Amy Perrin Ross - 869-885 Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico
by Denisse Añorve Bailon & Javier Picó-Guzmán & Sergio Cifuentes & Rogelio Trejo & Jeronimo Rodríguez Cid & Juan Jose Juarez-Vignon Whaley & Alan Alexis Heredia Zepeda & Raquel Gerson & Christian Patricio Camacho-Limas & José Fabián Martínez-Herrera & Diana Bonilla Molina & Efraín Camarín Sánchez & Daniela Shveid Gerson - 887-896 Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
by Sergio Cedillo & Almudena González-Domínguez & Yoana Ivanova-Markova & Rafael López López & Sara López-Tarruella Cobo & José Alberto Peña Pedrosa - 897-909 Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians
by Marion Tano & Pascal Paubel & Matthieu Ribault & Albane Degrassat-Théas - 911-922 Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off
by Maria Farris & Stephen Goodall & Richard Abreu Lourenco & Brendan Mulhern & Kathleen Manipis & Elena Meshcheriakova & Milena Lewandowska - 923-934 Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK
by Danny Gibson & Neil Branscombe & Neil Martin & Andrew Menzies-Gow & Priya Jain & Katherine Padgett & Florian Yeates - 935-943 The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System
by Sam Harper & Muralikrishnan Kartha & Stuart Mealing & Maurizio Pavanello & Luigi Bonavina - 945-959 Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial
by Ludovica Borsoi & Elisabetta Listorti & Oriana Ciani - 961-961 Correction: Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore
by Clarence Ong & Jamaica Briones & Zhi Zhen Lim & Nisha Suyien Chandran & Haur Yueh Lee & Benny Kaihui Li & Yik Weng Yew & Hwee-Lin Wee - 963-965 Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses
by Fatemeh Mirzayeh Fashami & Jean-Eric Tarride & Behnam Sadeghirad & Kimia Hariri & Amirreza Peyrovinasab & Mitchell Levine
September 2024, Volume 8, Issue 5
- 645-649 NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances
by Dawn Lee & Darren Burns & Ed Wilson - 651-664 Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers
by Diana Beatriz Bayani & Yihao Clement Lin & Chandramouli Nagarajan & Melissa G. Ooi & Allison Ching Yee Tso & John Cairns & Hwee Lin Wee - 665-678 Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment
by Jürgen Wasem & Yanic Heer & Eleni Karamasioti & Erwan Muros-Le Rouzic & Giuseppe Marcelli & Danilo Maio & Stefan Braune & Gisela Kobelt & Paul Dillon - 679-688 Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story
by She Hui Tan & Louise Gek Huang Goh & Benjamin Shao Kiat Ong & Darren Sze Guan Ng & Liang Lin & Raymond Chee Hui Ng & Bernard Yu-Hor Thong & Kwong Ng - 689-699 A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
by Paul Casabianca & Marc Massetti & François-Emery Cotte & Romain Moreau & Sarah Kassahun & Prianka Singh & Inkyu Kim & Anne-Françoise Gaudin & Guillaume Piessen & Henri Leleu - 701-714 Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
by Jonathan Salcedo & Daniel Hill-McManus & Chloë Hardern & Oyin Opeifa & Raffaella Viti & Ludovica Siviero & Antonio Saverio Roscini & Gennaro Martino - 715-725 Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
by Andrew Lloyd & Daniel Aggio & Caleb Dixon & Ernest H. Law & Thomas Price - 727-738 Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina
by Natalia Espinola & Constanza Silvestrini & Carla Colaci & Daniela Sugg & Carlos Rojas-Roque & Jesica Coelli & Federico Augustovski - 739-753 A Cost Evaluation of COVID-19 Remote Home Monitoring Services in England
by Sonila M. Tomini & Efthalia Massou & Nadia E. Crellin & Naomi J. Fulop & Theo Georghiou & Lauren Herlitz & Ian Litchfield & Pei Li Ng & Chris Sherlaw-Johnson & Manbinder S. Sidhu & Holly Walton & Stephen Morris - 755-764 ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation
by Richard Nicholas & Erik Scalfaro & Rachel Dorsey & Zuzanna Angehrn & Judit Banhazi & Roisin Brennan & Nicholas Adlard - 765-772 Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review
by Vittoria Ardito & Ludovico Cavallaro & Michael Drummond & Oriana Ciani - 773-781 Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study Protocol
by Surachat Ngorsuraches & Tim C. Lai & Rebecca Habermann & Yolanda Wheeler & William Meador - 783-783 Correction: NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances
by Dawn Lee & Darren Burns & Ed Wilson - 785-785 Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
by Sydney George & Justin Carrico & Katherine A. Hicks & Dessi Loukov & Cheryl Ng & Jessica Regan & Nikolaos Giannelos
July 2024, Volume 8, Issue 4
- 507-510 Whither Decision-Analytic Modelling-Based Economic Evaluation for Health Care Decision Making?
by Rachael Maree Hunter & Matthew Franklin - 511-524 A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
by Sudewi Mukaromah Khoirunnisa & Fithria Dyah Ayu Suryanegara & Lisa Aniek Jong & Didik Setiawan & Maarten Jacobus Postma - 525-537 Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension
by Rod S. Taylor & Anthony Bentley & Kaylie Metcalfe & Melvin D. Lobo & Ajay J. Kirtane & Michel Azizi & Christopher Clark & Kieran Murphy & Jennifer H. Boer & Marjolijn Keep & An Thu Ta & Neil C. Barman & Garrett Schwab & Ron Akehurst & Roland E. Schmieder - 539-557 Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France
by Gérard Pouvourville & Manon Breau-Brunel & Véronique Loncle-Provot & Ekkehard Beck & Loïg Gaugain & Gaëlle Nachbaur & Céline Pribil - 559-568 Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country
by Najmeh Moradi & Leila Zarei & Narges Hajimoladarvish & Zahra Meshkani & Marzieh Zanganeh & Jafar Babapour & Kamran Bagheri Lankarani - 569-583 Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model
by Emma McManus - 585-598 Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
by Carlos Rojas-Roque & Constanza Silvestrini & Fernando Argento & Daniela Sugg & Federico Augustovski & Jesica Coelli & Natalia Espinola - 599-609 Cost of Care for Non-communicable Diseases: Which Types of Healthcare Providers are the Most Economical in India’s Chhattisgarh State?
by Samir Garg & Narayan Tripathi & Kirtti Kumar Bebarta - 611-626 A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales
by Colin Burke & Catriona Crossan & Emma Tyas & Matthew Hemstock & Dawn Lee & Sally Bowditch - 627-640 Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs
by Micha J. Pilz & Simone Seyringer & Imad Al-Naesan & Madeleine T. King & Andrew Bottomley & Richard Norman & Lisa Schlosser & Tobias Hell & Eva Maria Gamper - 641-641 Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension
by Rod S. Taylor & Anthony Bentley & Kaylie Metcalfe & Melvin D. Lobo & Ajay J. Kirtane & Michel Azizi & Christopher Clark & Kieran Murphy & Jennifer H. Boer & Marjolijn Keep & An Thu Ta & Neil C. Barman & Garrett Schwab & Ron Akehurst & Roland E. Schmieder - 643-643 Correction: Developing a Natural History Model for Duchenne Muscular Dystrophy
by Jonathan Broomfield & M. Hill & F. Chandler & M. J. Crowther & J. Godfrey & M. Guglieri & J. Hastie & J. Larkindale & J. Mumby-Croft & E. Reuben & F. Woodcock & K. R. Abrams
May 2024, Volume 8, Issue 3
- 347-357 Introducing Open Science in Teaching Health Economic Modelling
by Xavier G. L. V. Pouwels & Hendrik Koffijberg - 359-371 Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease
by Syed G. Mohiuddin & Mary E. Ward & William Hollingworth & Jessica C. Watson & Penny F. Whiting & Howard H. Z. Thom - 373-387 Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany
by Niklaus Meier & Hendrik Fuchs & Katya Galactionova & Cedric Hermans & Mark Pletscher & Matthias Schwenkglenks - 389-401 Behind the Scenes: A Qualitative Investigation of Interviewers' Performance in EQ-5D Valuation Studies
by Carlotta Varriale & Giovanni Andrulli & Michela Meregaglia & Fanni Rencz & Aureliano Paolo Finch - 403-416 Cost-Effectiveness Analysis of Digital Breast Tomosynthesis Added to Synthetic Mammography in Breast Cancer Screening in Brazil
by Henrique Lima Couto & Ludmila Peres Gargano & Vilmar Marques Oliveira & Bertha Andrade Coelho & Eduardo Carvalho Pessoa & Augusto Tufi Hassan & Agnaldo Lopes Silva & Linei Augusta Brolini Delle Urban & Luciano Chala Fernandes & Nisha Sharma & Ritse Mann & Stuart A McIntosh & Fernando Zanghelini - 417-429 An Economic Evaluation of a Streamlined Day-Case Atrial Fibrillation Ablation Protocol and Conventional Cryoballoon Ablation versus Antiarrhythmic Drugs in a UK Paroxysmal Atrial Fibrillation Population
by Joe W. E. Moss & Derick Todd & Lukasz Grodzicki & Beatrice Palazzolo & Richard Mattock & Stuart Mealing & Maxim Souter & Benedict Brown & Tom Bromilow & Damian Lewis & James McCready & Muzahir Tayebjee & Ewen Shepherd & Thiagarajah Sasikaran & Clare Coyle & Eleni Ismyrloglou & Nicholas A. Johnson & Prapa Kanagaratnam - 431-443 Identification and prioritisation of items for a draft participant-reported questionnaire to measure use of social care, informal care, aids and adaptations
by Kirsty M. Garfield & Gail A. Thornton & Samantha Husbands & Ailsa Cameron & William Hollingworth & Sian M. Noble & Paul Roy & Joanna C. Thorn - 445-457 Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
by Christian Bührer & Thomas Paling & Richard Gale & Tatiana Paulo & Marloes Bagijn - 459-469 Health-Related Quality of Life and Economic Burden Among Hospitalized Children with Hand, Foot, and Mouth Disease: A Multiregional Study in China
by Ting Zhou & Hongfei Hu & Junyang Gao & Hongjie Yu & Mark Jit & Pei Wang - 471-480 Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus
by Olga Pitsillidou & Panagiotis Petrou & M. J. Postma - 481-492 Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
by Sydney George & Justin Carrico & Katherine A. Hicks & Dessi Loukov & Cheryl Ng & Jessica Regan & Nikolaos Giannelos - 493-505 A Canadian Simulation Model for Major Depressive Disorder: Study Protocol
by Shahzad Ghanbarian & Gavin W. K. Wong & Mary Bunka & Louisa Edwards & Sonya Cressman & Tania Conte & Sandra Peterson & Rohit Vijh & Morgan Price & Christian Schuetz & David Erickson & Linda Riches & Ginny Landry & Kim McGrail & Jehannine Austin & Stirling Bryan
March 2024, Volume 8, Issue 2
- 147-170 Health Economic Evaluations of Hemochromatosis Screening and Treatment: A Systematic Review
by Malvina Hoxha & Visar Malaj & Bruno Zappacosta - 171-190 A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma
by Fei Fei Liu & Meaghan Bartlett & Samantha Craigie - 191-203 Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models
by Tim Reason & William Rawlinson & Julia Langham & Andy Gimblett & Bill Malcolm & Sven Klijn - 205-220 Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models
by Tim Reason & Emma Benbow & Julia Langham & Andy Gimblett & Sven L. Klijn & Bill Malcolm - 221-233 The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals
by Jose Luis Calleja & Jaime Espin & Ankita Kaushik & Manuel Hernandez-Guerra & Rob Blissett & Alon Yehoshua & Adam Igloi-Nagy - 235-249 Cost-Utility Analysis of Total Ankle Replacement Compared with Ankle Arthrodesis for Patients Aged 50–85 Years with End-Stage Ankle Osteoarthritis: The TARVA Study
by Andrew J. Goldberg & Ekaterina Bordea & Kashfia Chowdhury & Iva Hauptmannova & James Blackstone & Deirdre Brooking & Elizabeth L. Deane & Stephen Bendall & Andrew Bing & Chris Blundell & Sunil Dhar & Andrew Molloy & Steve Milner & Mike Karski & Steve Hepple & Malik Siddique & David T. Loveday & Viren Mishra & Paul Cooke & Paul Halliwell & David Townshend & Simon S. Skene & Caroline J. Doré - 251-261 From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
by Elvio Emanuele Rossini & Carlotta Galeone & Chiara Lucchetti & Claudio Jommi - 263-276 Health State Utilities Associated with False-Positive Cancer Screening Results
by Louis S. Matza & Timothy A. Howell & Eric T. Fung & Sam M. Janes & Michael Seiden & Allan Hackshaw & Lincoln Nadauld & Hayley Karn & Karen C. Chung - 277-289 Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden
by Maria Polyzoi & Mattias Ekman & Anja Reithmeier & Johanna Jacob & Emma Karlsson & Evelina Bertranou & Barbro Linderholm & Robert Hettle - 291-302 Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain
by Rosa María Romero Jiménez & Pedro Herranz Pinto & Minia Campos Domínguez & Susana Aceituno Mata & Alba Bellmunt & Miriam Prades & Daniel Arumi & Irene Hernández-Martín & Valeria Herrera-Lasso & Noelia Llevat & Alfonso Lossada Juste & Francisco José Rebollo Laserna - 303-311 An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund
by Laura A. Trigg & Maxwell S. Barnish & Samuel Hayward & Naomi Shaw & Louise Crathorne & Brad Groves & John Spoors & Thomas Strong & G. J. Melendez-Torres & Caroline Farmer - 313-331 Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark
by Milanne Maria Johanna Galekop & Carin Uyl-de Groot & William Ken Redekop - 333-343 Understanding the Natural History of Chronic Hepatitis D: Proposal of a Model for Cost-Effectiveness Studies
by Ankita Kaushik & Geoffrey Dusheiko & Chong Kim & Nathaniel J. Smith & Csilla Kinyik-Merena & Gian Luca Tanna & Robert J. Wong - 345-345 Correction: From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
by Elvio Emanuele Rossini & Carlotta Galeone & Chiara Lucchetti & Claudio Jommi
January 2024, Volume 8, Issue 1
- 5-18 The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain
by Bérengère Macabeo & Théophile Rotrou & Aurélie Millier & Clément François & Philippe Laramée - 19-30 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
by Laurent Fauchier & Nicolas Lamblin & Jean Tardu & Lucile Bellier & Harinala Groyer & Deborah Ittah & Julien Chollet & Stephan Linden & Pierre Levy - 31-47 Specialist Palliative Care and Health Care Costs at the End of Life
by Patricia Kenny & Dan Liu & Denzil Fiebig & Jane Hall & Jared Millican & Sanchia Aranda & Kees Gool & Philip Haywood - 49-63 United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument
by Madeleine T. King & D. A. Revicki & R. Norman & F. Müller & R.C. Viney & A. S. Pickard & D. Cella & J. W. Shaw - 65-78 Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment
by Christian Speckemeier & Carina Abels & Klemens Höfer & Anja Niemann & Jürgen Wasem & Anke Walendzik & Silke Neusser - 79-89 Developing a Natural History Model for Duchenne Muscular Dystrophy
by Jonathan Broomfield & M. Hill & F. Chandler & M. J. Crowther & J. Godfrey & M. Guglieri & J. Hastie & J. Larkindale & J. Mumby-Croft & E. Reuben & F. Woodcock & K. R. Abrams - 91-101 Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
by Andrea Favre-Bulle & Min Huang & Amin Haiderali & Arjun Bhadhuri - 103-114 Cost of Patients with Alzheimer’s Disease in Spain According to Disease Severity
by Laura Gómez Maldonado & Ricardo de Mora-Figueroa & Angélica López-Angarita & Paulina Maravilla-Herrera & María Merino - 115-118 Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates
by Jeremy Costin & Morgane C. Mouslim & Mariana P. Socal & Antonio Trujillo - 119-131 Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis
by Joost G. E. Verbeek & Karen Sluis & Marieke A. Vollebergh & Johanna W. Sandick & Wim H. Harten & Valesca P. Retèl - 133-146 Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)
by Hilary M. DuBrock & Hayley D. Germack & Marjolaine Gauthier-Loiselle & Jörg Linder & Ambika Satija & Ameur M. Manceur & Martin Cloutier & Patrick Lefebvre & Sumeet Panjabi & Robert P. Frantz
November 2023, Volume 7, Issue 6
- 863-875 Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
by Marty Chaplin & Rebecca Bresnahan & Nigel Fleeman & James Mahon & Rachel Houten & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Pinki Munot - 877-886 Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review
by Bereket Bahiru Tefera & Desalegn Getnet Demsie & Adane Yehualaw & Chernet Tafere & Kebede Feyisa & Malede Berihun Yismaw & Belayneh Kefale & Zewdu Yilma - 887-914 Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews
by Gillian Eaglestone & Evdoxia Gkaintatzi & Harmony Jiang & Charlotte Stoner & Rosana Pacella & Paul McCrone - 915-926 Trade-Offs between Vaccine Effectiveness and Vaccine Safety: Personal versus Policy Decisions
by Semra Ozdemir & Sean Ng & Vinh Anh Huynh & Axel Mühlbacher & Hiang Khoon Tan & Eric Andrew Finkelstein - 927-940 Hospital Resource Utilization and Costs in Patients with Heart Failure in France
by Frank Chemouni & Tiffany Chihiro Nishikawa & Harinala Groyer & Oumou Diaby & Julien Chollet & Deborah Ittah - 941-950 Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma
by Elisabeth F. P. Peterse & Elisabeth J. M. Verburg-Baltussen & Alexa Stewart & Fei Fei Liu & Christopher Parker & Maarten Treur & Bill Malcolm & Sven L. Klijn - 951-961 Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data
by Luis Phillipe Nagem Lopes & Alexander Itria & Luciane Cruz Lopes - 963-974 The EQ-5D-3L Valuation Study in Pakistan
by Madeeha Malik & Ning Yan Gu & Azhar Hussain & Bram Roudijk & Fredrick Dermawan Purba - 975-985 Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States
by Ahmed Salem & Elizabeth M. La & Desmond Curran & Brandon J. Patterson & Justin Carrico & Stéphane Lorenc & Katherine A. Hicks & Sara Poston & Christopher F. Carpenter - 987-995 Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study
by Claire Oliveira & Bryan Tanner - 997-1006 Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada
by Reka E. Pataky & Stirling Bryan & Mohsen Sadatsafavi & Stuart Peacock & Dean A. Regier - 1007-1013 Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality
by L. A. Jong & X. Li & S. Emamipour & S. Werf & M. J. Postma & P. R. Dijk & T. L. Feenstra - 1015-1015 Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
by Marty Chaplin & Rebecca Bresnahan & Nigel Fleeman & James Mahon & Rachel Houten & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Pinki Munot
September 2023, Volume 7, Issue 5
- 679-708 Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review
by Jorien Laermans & Hans Van Remoortel & Hans Scheers & Bert Avau & Jørgen Georgsen & Susan Nahirniak & Nadine Shehata & Simon J. Stanworth & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 709-722 Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis
by Kenar D. Jhaveri & Mark E. Bensink & Martin Bunke & Jonathon A. Briggs & David M. W. Cork & Anushya Jeyabalan - 723-738 Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review
by Nick Jovanoski & Seye Abogunrin & Danilo Maio & Rossela Belleli & Pollyanna Hudson & Sneha Bhadti & Libby G. Jones - 739-750 Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
by Tom Bromilow & Hayden Holmes & Laura Coote & Sam Woods & Joshua Pink - 751-764 Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark
by Anne Høy Seemann Vestergaard & Lars Holger Ehlers & Mette Asbjoern Neergaard & Christian Fynbo Christiansen & Jan Brink Valentin & Søren Paaske Johnsen - 765-776 Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data
by Anna Philipson & Lars Hagberg & Liselotte Hermansson & Jan Karlsson & Emma Ohlsson-Nevo & Linda Ryen - 777-792 Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
by Francis Shupo & Keith R. Abrams & Zanfina Ademi & Grace Wayi-Wayi & Natasa Zibelnik & Matt Kirchmann & Carolyn Rutherford & Kelly Makarounas-Kirchmann - 793-809 Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study
by Ikennah L. Browne & Andrew J. Sutton & Wei Zhang - 811-822 Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases
by Chitra Karki & Dominick Latremouille-Viau & Inmaculada Gilaberte & Gary Hantsbarger & Hela Romdhani & Amy L. Lightner - 823-840 Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis
by Edward V. Loftus & Ashwin N. Ananthakrishnan & Wan-Ju Lee & Yuri Sanchez Gonzalez & Kristina A Fitzgerald & Kori Wallace & Wen Zhou & Leighann Litcher-Kelly & Sarah B. Ollis & Sylvia Su & Silvio Danese - 841-849 A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico
by Juan Carlos Garnica-Cuellar & Enrique Morales-Villegas & Carmen Alicia López-Forero & Bárbara Monroy-Cruz & Bhrugu Pariti & Swati Deshwal & Manisha Sekharan & Mariana Osorio-Hernández & Ida Caterina García-Appendini - 851-860 Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis
by Andrew Khair & Tray Brown & Marie Markert & Carsten Rødseth Barsøe & Gaurang S. Daftary & Patrick W. Heiser - 861-861 Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
by Tom Bromilow & Hayden Holmes & Laura Coote & Sam Woods & Joshua Pink
July 2023, Volume 7, Issue 4
- 507-523 A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R
by Yi-Shu Lin & James F O’Mahony & Joost Rosmalen - 525-536 Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rebecca Bresnahan & Rachel Houten & Janette Greenhalgh & Sarah Nevitt & James Mahon & Sophie Beale & Angela Boland & Devarshi Bhattacharyya & Yenal Dundar & Joanne McEntee & Shreyans Gandhi & Nigel Fleeman & Marty Chaplin - 537-552 Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania
by Hiral Anil Shah & Tim Baker & Carl Otto Schell & August Kuwawenaruwa & Khamis Awadh & Karima Khalid & Angela Kairu & Vincent Were & Edwine Barasa & Peter Baker & Lorna Guinness - 553-565 Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
by Mackenzie Mills & Panos Kanavos - 567-577 Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
by Esra Çakar & César Oniangue-Ndza & Ralph P. Schneider & Sven L. Klijn & Ursula M. Vogl & Christian Rothermundt & Jessica R. May - 579-591 Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
by Ryan Pulleyblank & Nikolaj Birk Larsen - 593-603 Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing
by Fiona Koster & Marc R. Kok & Jaco Kooij & Geeke Waverijn & Angelique E. A. M. Weel-Koenders & Deirisa Lopes Barreto - 605-615 Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
by Cesarius Singgih Wahono & Laniyati Hamijoyo & Yuriawati Hendrawan & Liyana Rakinaturia & Neha Mittal & Prabal Khanna & Minal Jain & Harry Isbagio - 617-626 Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
by Julie Vanderpoel & Bruno Emond & Isabelle Ghelerter & Katherine Milbers & Marie-Hélène Lafeuille & Patrick Lefebvre & Lorie A. Ellis - 627-638 Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia
by Eliza Kruger & Daniel Aggio & Hayley Freitas & Andrew Lloyd - 639-653 Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
by Megane Caillon & Benoit Brethon & Chrissy Beurden-Tan & Romain Supiot & Antoine Mezo & Jean-Vannak Chauny & Istvan Majer & Arnaud Petit - 655-663 Effect of Perioperative Oral Vitamin C Supplementation on In-Hospital Postoperative Medication Costs for Cardiac Surgery Patients: A Prospective, Single-Centre, Randomised Clinical Trial
by Jan Heerman & Charlotte Boydens & Silvie Allaert & Koen Cathenis & Koen Deryckere & Henk Vanoverschelde - 665-678 Systematic Review and Cost-Consequence Analysis of Ambu aScope 5 Broncho Compared with Reusable Flexible Bronchoscopes: Insights from Two US University Hospitals and an Academic Institution
by Anders E. Kristensen & Jonathan S. Kurman & D. K. Hogarth & Sonali Sethi & Sabrina S. Sørensen
May 2023, Volume 7, Issue 3
- 337-344 Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility
by Chris Skedgel & Patricia Cubi-Molla & David Mott & Sofia Gameiro & Jacky Boivin & Hareth Al-Janabi & John Brazier & Marie Markert & Fredrik L. Andersson & Mireia Jofre-Bonet - 345-358 Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachel Houten & Nigel Fleeman & James Mahon & Marty Chaplin & Katherine Edwards & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Zafar Malik & Carlo Palmieri - 359-371 Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review
by Tiziana Magni & Chiara Ragni & Nicola Pelizzi & Sheetal Sharma & Lucia Perez-Kempner & Erika Turkstra & Jyothsna Nathani & Martina Orlovic & Natalia Meshchenkova - 373-381 The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency
by Claudio Jommi & Carlotta Galeone - 383-392 Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
by Taihang Shao & Mingye Zhao & Leyi Liang & Lizheng Shi & Wenxi Tang - 393-404 Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
by Aryana Sepassi & Ila M. Saunders & Mark Bounthavong & Randy A. Taplitz & Cathy Logan & Jonathan H. Watanabe - 405-416 A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
by Paolo Angelo Cortesi & Carla Fornari & Paolo Gisondi & Florenzo Iannone & Ippazio Cosimo Antonazzo & Elisabetta Aloisi & Martina Fiocchi & Daniela Ritrovato & Lorenzo Giovanni Mantovani - 417-429 Economic Evaluation Comparing Virtual Reality with Child Life Programming for Non-sedated Pediatric Medical Imaging: A Cost-Consequence Analysis
by John Jacob & Chelsea Stunden & Dhayanand Deenadayalan & Luke Thomas - 431-441 Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain
by A. M. Alonso Torres & A. G. Arévalo Bernabé & N. Becerril Ríos & M. F. Hellín Gil & J. M. Martínez Sesmero & V. Meca Lallana & Ll. Ramió-Torrentà & A. Rodríguez-Antigüedad & L. Gómez Maldonado & I. Triana Junco & M. Gómez-Barrera & N. Espinoza Cámac & I. Oyagüez - 443-454 Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
by Amy Dymond & Will Green & Mary Edwards & Maria Angeles Lopez Pont & Girish Gupta - 455-467 Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
by Andre Verhoek & Parneet Cheema & Barbara Melosky & Benoit Samson & Frances A. Shepherd & Filippo Marinis & Thomas John & Yi-Long Wu & Bart Heeg & Nadia Dalfsen & Benjamin Bracke & Miguel Miranda & Simon Shaw & Daniel Moldaver - 469-477 Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
by Owen Alan Edwards Cooper & Ola Ghatnekar & Natalia Piglowska & Charlie A. Smith & Paul Swinburn & James W. F. Catto & Günter Niegisch & Jørn Skibsted Jakobsen - 479-491 Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands
by Rachel H. P. Schreurs & Arina J. Cate-Hoek & Hugo Cate & Manuela A. Joore - 493-505 Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial
by Charles Yan & Jeff Round & Ilke Akpinar & Chantal E. Atwood & Lesly Deuchar & Mohit Bhutani & Richard Leigh & Michael K. Stickland
March 2023, Volume 7, Issue 2
- 163-173 The Impact of Digital Health Interventions for the Management of Type 2 Diabetes on Health and Social Care Utilisation and Costs: A Systematic Review
by Tiyi Morris & Fiona Aspinal & Jean Ledger & Keyi Li & Manuel Gomes - 175-187 The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
by Dawn Lee & Grant McCarthy & Omar Saeed & Rachel Allen & Kinga Malottki & Fleur Chandler - 189-197 Estimating the Incidence-Based Cost of Illness Due to Hematopoietic Stem Cell Transplantation Using One-Year Insurance Claim Data in Korea
by Sol Kwon & Hye-Young Kang - 199-216 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
by Anuja Chatterjee & Gijs Wetering & Ron Goeree & Carolyn Owen & Anne Marie Desbois & Stephane Barakat & Beenish S. Manzoor & Kavita Sail - 217-228 Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods
by R. Brett McQueen & Nicholas D. Mendola & Ivett Jakab & Jeffrey Bennett & Kavita V. Nair & Bertalan Németh & András Inotai & Zoltán Kaló - 229-241 Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
by Paulo Martins & Björn Vandewalle & Jorge Félix & Carlos M. Capela & João J. Cerqueira & António V. Salgado & Diana G. Ferreira & Isabel Monteiro - 243-255 A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
by Rajiv Mallick & Rashad Carlton & Joris Stiphout - 257-271 Attributable Patient Cost of Antimicrobial Resistance: A Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana
by Evans Otieku & Ama Pokuaa Fenny & Appiah-Korang Labi & Alex Owusu Ofori & Joergen Anders Lindholm Kurtzhals & Ulrika Enemark - 273-284 Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
by Shanlian Hu & Zhiliu Tang & James P. Harrison & Nadine Hertel & John R. Penrod & Jessica R. May & Ariadna Juarez-Garcia & Orban Holdgate - 285-298 Cost-Utility Analysis of the Caresyntax Platform to Identify Patients at Risk of Surgical Site Infection Undergoing Colorectal Surgery
by Eoin Moloney & Atefeh Mashayekhi & Mehdi Javanbakht & Mohsen Rezaei Hemami & Michael Branagan-Harris - 299-312 The Burden of Caring for Individuals with Tuberous Sclerosis Complex (TSC) Who Experience Epileptic Seizures: A Descriptive UK Survey
by Hanna Skrobanski & Kishan Vyas & Sally Bowditch & Lena Hubig & Edward Dziadulewicz & Louise Fish & Pooja Takhar & Siu Hing Lo - 313-320 A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America
by Aaron Winn & Anirban Basu & Scott D. Ramsey - 321-335 The Cost-Effectiveness of a Dance and Yoga Intervention for Girls with Functional Abdominal Pain Disorders
by Anna Philipson & Anna Duberg & Lars Hagberg & Sofie Högström & Lars Lindholm & Margareta Möller & Linda Ryen
January 2023, Volume 7, Issue 1
- 3-36 A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
by Conor McCloskey & María Toboso Ortega & Sunita Nair & Maria João Garcia & Federico Manevy - 37-46 Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
by F. Felizzi & Aino Launonen & P.-O. Thuresson - 47-48 Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
by F. Felizzi & Aino Launonen & P.-O. Thuresson - 49-62 Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
by Karan K. Shah & Melina Willson & Blaise Agresta & Rachael L. Morton - 63-63 Correction to: Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
by Karan K. Shah & Melina Willson & Blaise Agresta & Rachael L. Morton - 65-76 Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study
by Tetsuya Matsumoto & Akira Yuasa & Ryan Miller & Clive Pritchard & Takahisa Ohashi & Amer Taie & Jason Gordon - 77-91 “Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England
by Jiyeon Kang & John Cairns - 93-110 Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis
by Mehdi Javanbakht & Jesse Fishman & Eoin Moloney & Peter Rydqvist & Amir Ansaripour - 111-120 Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia
by Louisa G. Gordon & C. Wood & R. W. Tothill & P. M. Webb & P. Schofield & L. Mileshkin - 121-138 Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
by Meryl Brod & Michael Højby Rasmussen & Suzanne Alolga & Jane F. Beck & Donald M. Bushnell & Kai Wai Lee & Aristides Maniatis - 139-148 Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai Population
by Krittaphas Kangwanrattanakul - 149-161 Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective
by François-Xavier Chalet & Teodora Bujaroska & Evi Germeni & Nizar Ghandri & Emilio T. Maddalena & Kushal Modi & Abisola Olopoenia & Jeffrey Thompson & Matteo Togninalli & Andrew H. Briggs
November 2022, Volume 6, Issue 6
- 773-786 Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification
by Matthew Fabbro & Kirah Hahn & Olivia Novaes & Mícheál Ó’Grálaigh & James F. O’Mahony - 787-797 The Cost of Flexible Bronchoscopes: A Systematic Review and Meta-analysis
by Carina Østervig Andersen & Helena Travis & Emilie Dehlholm-Lambertsen & Rasmus Russell & Emmelie Ploug Jørgensen - 799-809 Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
by Keith B. Allen & James E. Alexander & Joshua N. Liberman & Susan Gabriel - 811-822 Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
by David Elsea & Lin Fan & Adela Mihai & Fadoua El Moustaid & Daniel Simmons & Matthew Monberg & Dominic Muston - 823-836 An EQ-5D-5L Value Set for Belgium
by Nicolas Bouckaert & Irina Cleemput & Stephan Devriese & Sophie Gerkens - 837-846 Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
by Fabio Gil & Fabian Juliao-Baños & Luisa Amador & Natalia Castano & Juan Manuel Reyes - 847-857 What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care
by Megan Dale & Sarah F Bell & Susan O’Connell & Cerys Scarr & Kathryn James & Miriam John & Rachel E Collis & Peter W Collins & Grace Carolan-Rees - 859-870 Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
by Moogeh Baharnoori & Virender Bhan & Fraser Clift & Kimberly Thomas & Soukaïna Mouallif & Nicholas Adlard & Philip Cooney & François Blanchette & Barkha P. Patel & Daniel Grima - 871-880 Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
by Andrew Blauvelt & Nianwen Shi & Russel Burge & Bilal Atiya & Baojin Zhu & Najwa Somani & Terri Ridenour & Carolyn R. Lew & Nicole M. Zimmerman & Mwangi J. Murage - 881-892 Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
by Holly Cranmer & David Trueman & Elise Evers & Fionn Woodcock & Tanja Podkonjak - 893-895 Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates
by Rachel Milstein Breslau & Joshua T. Cohen & Daniel A. Ollendorf & Peter J. Neumann - 897-897 Correction to: Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
by Keith B. Allen & James E. Alexander & Joshua N. Liberman & Susan Gabriel - 899-899 Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
by David Elsea & Lin Fan & Adela Mihai & Fadoua El Moustaid & Daniel Simmons & Matthew Monberg & Dominic Muston
September 2022, Volume 6, Issue 5
- 631-635 Using Health Economics to Inform Immunization Policy Across All Levels of Government
by Ellen Rafferty & Laura Reifferscheid & Ali Assi & Shannon E. MacDonald - 637-646 How are Companion Diagnostics Considered in Economic Evaluations of Oncology Treatments? A Review of Health Technology Assessments
by Melissa Gomez Montero & Houcine El Alili & Mahmoud Hashim & Peter Wigfield & Mariya Dimova & Ralph Riley & Katie Pascoe - 647-656 Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
by Lotte Westerink & Jelmer Lennart Jens Nicolai & Maarten Jacobus Postma & Job Frank Martien Boven & Cornelis Boersma - 657-668 Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina
by Osvaldo Ulises Garay & Gonzalo Guiñazú & Yolanda Patricia Adamczuk & Cristina Duboscq - 669-679 Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment
by Alireza Darrudi & Rajabali Daroudi & Masud Yunesian & Ali Akbari Sari - 681-696 Cost-Effectiveness Analysis of a Medial Meniscus Replacement Prosthesis for the Treatment of Patients with Medial Compartment Pain in the United Kingdom
by Mehdi Javanbakht & Atefeh Mashayekhi & Angeline Carlson & Eoin Moloney & Martyn Snow & James Murray & Tim Spalding - 697-710 Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
by Timothy Baker & Helen Johnson & Srividya Kotapati & Andriy Moshyk & Melissa Hamilton & Murat Kurt & Victoria Federico Paly - 711-721 The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey
by Marie Louise Edwards & Perry T. Yin & Michael Kuehn & Keith Bratti & Noam Kirson & Anupam Jena & Scott Howell - 723-733 Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX)
by Rachael Hunter & Alice Beardmore-Gray & Melanie Greenland & Louise Linsell & Edmund Juszczak & Pollyanna Hardy & Anna Placzek & Andrew Shennan & Neil Marlow & Lucy C. Chappell - 735-743 Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland
by Elisabeth Brock & Giorgio Moschovitis & Micha T. Maeder & Otmar Pfister - 745-756 Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance Schemes
by Maninder Pal Singh & Shankar Prinja & Kavitha Rajsekar & Praveen Gedam & Vipul Aggarwal & Oshima Sachin & Jyotsna Naik & Ajai Agarwal & Sanjay Kumar & Setu Sinha & Varsha Singh & Prakash Patel & Amit C. Patel & Rajendra Joshi & Avijit Hazra & Raghunath Misra & Divya Mehrotra & Sashi Bhusan Biswal & Ankita Panigrahy & Kusum Lata Gaur & Jai Prakash Pankaj & Dharmesh Kumar Sharma & Kondeti Madhavi & Pulaganti Madhusudana & K. Narayanasamy & A. Chitra & Gajanan D. Velhal & Amit S. Bhondve & Rakesh Bahl & Amit Sachdeva & Sharminder Kaur & Anu Nagar & Balram Bhargava - 757-771 The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
by Thomas Ward & Tray Brown & Ruth D. Lewis & Melodi Kosaner Kliess & Antonio Ramirez Arellano & Carol M. Quinn
July 2022, Volume 6, Issue 4
- 469-481 Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis
by Zachary Baldwin & Boshen Jiao & Anirban Basu & Joshua Roth & M. A. Bender & Zizi Elsisi & Kate M. Johnson & Emma Cousin & Scott D. Ramsey & Beth Devine - 483-494 Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting
by Sabine Michelsen Raunbak & Anne Sig Sørensen & Louise Hansen & Flemming Skjøth & Torben Bjerregaard Larsen & Lars Holger Ehlers - 495-507 Costs and Effects of Implementing Digital Tomosynthesis in a Population-Based Breast Cancer Screening Program: Predictions Using Results from the To-Be Trial in Norway
by Tron Anders Moger & Åsne Holen & Berit Hanestad & Solveig Hofvind - 509-518 Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain
by Ángel Gil de Miguel & José María Eiros Bouza & Luis Ignacio Martínez Alcorta & Daniel Callejo & Carlos Miñarro & Laura Amanda Vallejo-Aparicio & Andrea García & Mónica Tafalla & María del Rosario Cambronero & Rubén Rodríguez & Laura Martin-Gomez - 519-537 Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
by Elisabetta Fenu & Vasily Lukyanov & Annabel Acs & Xenia Radu & Stephanie Stypa & Aren Fischer & John K. Marshall & Mark Oppe - 539-548 Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand
by Chunhuan Lao & Mohana Mondal & Marion Kuper-Hommel & Ian Campbell & Ross Lawrenson - 549-562 Cost-Effectiveness Analysis of Intravascular Targeted Temperature Management after Cardiac Arrest in England
by Mehdi Javanbakht & Atefeh Mashayekhi & Mohsen Rezaei Hemami & Michael Branagan-Harris & Thomas R Keeble & Mohsen Yaghoubi - 563-574 Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
by Matthew Reaney & Veleka Allen & Amy J. Sehnert & Liang Fang & Albert A. Hagège & Srihari S. Naidu & Iacopo Olivotto - 575-586 Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial
by Matthew Reaney & Prithvi Addepalli & Veleka Allen & John A. Spertus & Chantal Dolan & Amy J. Sehnert & Jennifer T. Fine - 587-594 Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial
by Anh Dam Tran & Angela M. Hong & Mai T. H. Nguyen & Gerald Fogarty & Victoria Steel & Elizabeth Paton & Rachael L. Morton - 595-603 Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms
by Michela Meregaglia & Rosanna Tarricone - 605-617 Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis
by Nafsika Afentou & Emma Frew & Samir Mehta & Natalie J. Ives & Rebecca L. Woolley & Elizabeth A. Brettell & Adam R. Khan & David V. Milford & Detlef Bockenhauer & Moin A. Saleem & Angela S. Hall & Ania Koziell & Heather Maxwell & Shivaram Hegde & Eric Finlay & Rodney D. Gilbert & Caroline Jones & Karl McKeever & Wendy Cook & Nicholas J. A. Webb & Martin T. Christian - 619-628 Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
by Zeki Kocaata & Thomas Wilke & Franz Fischer & Robert Welte & Hermann Einsele - 629-629 Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
by Anna-Maria Fontrier & Erica Visintin & Panos Kanavos
May 2022, Volume 6, Issue 3
- 315-328 Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
by Anna-Maria Fontrier & Erica Visintin & Panos Kanavos - 329-342 Community Distribution of Naloxone: A Systematic Review of Economic Evaluations
by Nelda Cherrier & Joanne Kearon & Robin Tetreault & Sophiya Garasia & Emmanuel Guindon - 343-354 Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
by Björn Eliasson & Åsa Ericsson & Adam Fridhammar & Andreas Nilsson & Sofie Persson & Barrie Chubb